KB707 trial for advanced solid tumors after other treatments
Treatments studied
Part of Cancer, Skin clinical trials.
This early-stage trial tests KB707 in people with locally advanced or metastatic solid tumors that have not responded well to standard treatments. If you qualify, you may receive KB707 to see how well it can shrink tumors or control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You expect to live more than 12 weeks
- Your health/activity level is good (ECOG 0 or 1)
- Doctors can measure your cancer on scans (measurable disease)
- You have a solid tumor that is advanced and either progressed, can’t tolerate, won’t take, or has no standard treatment left (your trial group may vary)
- If you’re in the melanoma groups (cohorts 5–6), you must have stage III unresectable or stage IV melanoma and have already tried a PD-1/PD-L1 treatment
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase study tests a new treatment in people with advanced (locally advanced or metastatic) solid tumors that have worsened or cannot be treated with standard therapies. It may help shrink tumors or slow growth, and it also helps doctors learn the safest way to use the medicine.
This Phase 1 trial studies a new experimental immunotherapy (MBS8) for people with advanced solid tumors, focusing first on safety and early signs of benefit. Depending on your cancer type and past treatments, you may receive MBS8 alone or combined with pembrolizumab.
This early-phase trial tests a new drug called BG-C9074, either alone or with other cancer treatments, for people with certain advanced solid tumors that have not responded to standard therapy. The goal is to see if it is safe and effective.
This trial tests a new medicine called KB707 for people with advanced cancers that affect the lungs. It uses a virus to deliver a gene that may help your immune system fight the tumor. The study is especially looking at people with lung cancer (NSCLC) or other solid tumors that have spread to the lungs and haven't responded to standard treatments.
This Phase 1 trial tests KM602, a new study treatment, in people with advanced solid tumors like melanoma or non-small cell lung cancer that have progressed after standard treatments. If you qualify, the goal is to see how the drug works and how safe it is in early research.
This study tests a new drug, KC1086, for people with advanced solid tumors that have not responded to standard treatments or for which no standard treatment exists. The goal is to find out if KC1086 is safe and possibly effective, and it may be an option if you are physically active and your organs are healthy.
Hear when a new Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.